Abstract:Over the past decade, there has been growing interest in the use of antibodies against intracellular targets. This is currently achieved through recombinant expression of the single chain variable fragment (scFv) antibody format within the cell, which is commonly referred to as an intrabody. This possesses a number of inherent advantages over RNA interference (iRNA). Firstly, the high specificity and affinity of intrabodies to target antigens is well-established, whereas iRNA has been frequently shown to exert multiple non-specific effects. Secondly, intrabodies being proteins possess a much longer active half-life compared to iRNA. Thirdly, when the active half-life of the intracellular target molecule is long, gene silencing through iRNA would be slow to yield any effect, whereas the effects of intrabody expression would be almost instantaneous. Lastly, it is possible to design intrabodies to block certain binding interactions of a particular target molecule, while sparing others. There is, however, various technical challenges faced with intrabody expression through the application of recombinant DNA technology. In particular, protein conformational folding and structural stability of the newly-synthesized intrabody within the cell is affected by reducing conditions of the intracellular environment. Also, there are overwhelming safety concerns surrounding the application of transfected recombinant DNA in human clinical therapy, which is required to achieve intrabody expression within the cell. Of particular concern are the various viral-based vectors that are commonly-used in genetic manipulation. A novel approach around these problems would be to look at the possibility of fusing protein transduction domains (PTD) to scFv antibodies, to create a ‘cell-permeable’ antibody or ‘Transbody’. PTD are short peptide sequences that enable proteins to translocate across the cell membrane and be internalized within the cytosol, through atypical secretory and internalization pathways. There are a number of distinct advantages that a ‘Transbody’ would possess over conventional intrabodies expressed within the cell. For a start, ‘correct’ conformational folding and disulfide bond formation can take place prior to introduction into the target cell. More importantly, the use of cell-permeable antibodies or ‘Transbodies’ would avoid the overwhelming safety and ethical concerns surrounding the direct application of recombinant DNA technology in human clinical therapy, which is required for intrabody expression within the cell. ‘Transbodies’ introduced into the cell would possess only a limited active half-life, without resulting in any permanent genetic alteration. This would allay any safety concerns with regards to their application in human clinical therapy.

A Biparatopic Intrabody Renders Vero Cells Impervious to Ricin Intoxication

A Biparatopic Intrabody Renders Vero Cells Impervious to Ricin Intoxication

Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody)

A Novel Designed Single Domain Antibody on 3-D Structure of Ricin A Chain Remarkably Blocked Ricin-Induced Cytotoxicity

Neutralization and Binding Activity of a Human Single-Chain Antibody to Ricin Toxin

Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies

A Recombinant Chimeric Protein Containing B Chains of Ricin and Abrin is an Effective Vaccine Candidate.

Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

Anti-ricin Toxin Human Neutralizing Antibodies and DMAbs Protection Against Ricin Toxin Poisoning

Development of Therapeutic Antibodies as Medical Countermeasures to Biological Agents in Defence Research and Development Canada , Suffield Research Centre

Contribution of an unusual CDR2 element of a single domain antibody in ricin toxin binding affinity and neutralizing activity

A novel neutralizing monoclonal antibody against cell-binding polypeptide of ricin.

Humanization and Characterization of an Anti-Ricin Neutralization Monoclonal Antibody

Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model

Active Immunity Induced by Passive Igg Post-Exposure Protection Against Ricin

Intrabodies against the EVH1 domain of Wiskott-Aldrich syndrome protein inhibit T cell receptor signaling in transgenic mice T cells

An anti-Shiga toxin VHH nanobody multimer protects mice against fatal toxicosis when administered intramuscularly as repRNA

Anti-Ricin Protective Monoclonal Antibodies

Novel Chimeric Anti-Ricin Antibody C4C13 with Neutralizing Activity Against Ricin Toxicity

Intrabody-Based Gene Therapeutic Strategy

Intranasal Stimulation of Long-Lasting Immunity Against Aerosol Ricin Challenge with Ricin Toxoid Vaccine Encapsulated in Polymeric Microspheres